90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.
Janik JE, Morris JC, O'Mahony D, Pittaluga S, Jaffe ES, Redon CE, Bonner WM, Brechbiel MW, Paik CH, Whatley M, Chen C, Lee JH, Fleisher TA, Brown M, White JD, Stewart DM, Fioravanti S, Lee CC, Goldman CK, Bryant BR, Junghans RP, Carrasquillo JA, Worthy T, Corcoran E, Conlon KC, Waldmann TA.
Janik JE, et al. Among authors: junghans rp.
Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13045-50. doi: 10.1073/pnas.1516107112. Epub 2015 Oct 5.
Proc Natl Acad Sci U S A. 2015.
PMID: 26438866
Free PMC article.